sterling pharma solutions limited

Live EstablishedMegaHealthy

sterling pharma solutions limited Company Information

Share STERLING PHARMA SOLUTIONS LIMITED

Company Number

05712796

Shareholders

saffron bidco limited

Group Structure

View All

Industry

Manufacture of basic pharmaceutical products

 

Registered Address

dudley, cramlington, northumberland, NE23 7QG

sterling pharma solutions limited Estimated Valuation

£308.6m

Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £308.6m based on a Turnover of £115.5m and 2.67x industry multiple (adjusted for size and gross margin).

sterling pharma solutions limited Estimated Valuation

£144m

Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £144m based on an EBITDA of £12.6m and a 11.44x industry multiple (adjusted for size and gross margin).

sterling pharma solutions limited Estimated Valuation

£90.4m

Pomanda estimates the enterprise value of STERLING PHARMA SOLUTIONS LIMITED at £90.4m based on Net Assets of £51.8m and 1.75x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Sterling Pharma Solutions Limited Overview

Sterling Pharma Solutions Limited is a live company located in northumberland, NE23 7QG with a Companies House number of 05712796. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in February 2006, it's largest shareholder is saffron bidco limited with a 100% stake. Sterling Pharma Solutions Limited is a established, mega sized company, Pomanda has estimated its turnover at £115.5m with healthy growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Sterling Pharma Solutions Limited Health Check

Pomanda's financial health check has awarded Sterling Pharma Solutions Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating2.5out of 5
positive_score

4 Strong

positive_score

2 Regular

positive_score

6 Weak

size

Size

annual sales of £115.5m, make it larger than the average company (£34.5m)

£115.5m - Sterling Pharma Solutions Limited

£34.5m - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 12%, show it is growing at a faster rate (5.5%)

12% - Sterling Pharma Solutions Limited

5.5% - Industry AVG

production

Production

with a gross margin of 26.3%, this company has a higher cost of product (35.8%)

26.3% - Sterling Pharma Solutions Limited

35.8% - Industry AVG

profitability

Profitability

an operating margin of 5.3% make it less profitable than the average company (7.4%)

5.3% - Sterling Pharma Solutions Limited

7.4% - Industry AVG

employees

Employees

with 654 employees, this is above the industry average (116)

654 - Sterling Pharma Solutions Limited

116 - Industry AVG

paystructure

Pay Structure

on an average salary of £57.2k, the company has an equivalent pay structure (£63.4k)

£57.2k - Sterling Pharma Solutions Limited

£63.4k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £176.6k, this is less efficient (£414.6k)

£176.6k - Sterling Pharma Solutions Limited

£414.6k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 212 days, this is later than average (63 days)

212 days - Sterling Pharma Solutions Limited

63 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 32 days, this is close to average (32 days)

32 days - Sterling Pharma Solutions Limited

32 days - Industry AVG

stockdays

Stock Days

it holds stock equivalent to 67 days, this is less than average (107 days)

67 days - Sterling Pharma Solutions Limited

107 days - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (9 weeks)

2 weeks - Sterling Pharma Solutions Limited

9 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 85.7%, this is a higher level of debt than the average (43.6%)

85.7% - Sterling Pharma Solutions Limited

43.6% - Industry AVG

STERLING PHARMA SOLUTIONS LIMITED financials

EXPORTms excel logo

Sterling Pharma Solutions Limited's latest turnover from March 2024 is £115.5 million and the company has net assets of £51.8 million. According to their latest financial statements, Sterling Pharma Solutions Limited has 654 employees and maintains cash reserves of £8 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Turnover115,470,000130,411,000118,573,00082,449,00068,206,00056,444,00055,428,00037,853,00031,902,00022,903,00028,776,00034,505,00042,171,00037,240,00031,746,000
Other Income Or Grants000000000000000
Cost Of Sales85,088,00084,276,00075,836,00058,619,00050,862,00045,272,00041,865,00032,343,00028,184,00023,572,00027,229,00028,798,00034,328,00031,884,00030,365,000
Gross Profit30,382,00046,135,00042,737,00023,830,00017,344,00011,172,00013,563,0005,510,0003,718,000-669,0001,547,0005,707,0007,843,0005,356,0001,381,000
Admin Expenses24,216,00015,951,00011,512,0007,251,0003,215,0002,862,0002,389,0001,369,0001,154,000800,000930,0001,112,0001,200,0001,646,0003,252,000
Operating Profit6,166,00030,184,00031,225,00016,579,00014,129,0008,310,00011,174,0004,141,0002,564,000-1,469,000617,0004,595,0006,643,0003,710,000-1,871,000
Interest Payable22,631,00015,208,0009,570,0007,812,0003,489,0001,990,0001,546,0001,689,0001,281,0001,022,000999,000863,0001,706,0001,840,0001,715,000
Interest Receivable5,229,0005,010,0002,876,0001,569,000415,00094,0000000018,00034,00026,00018,000
Pre-Tax Profit-11,236,00019,986,00024,531,00010,336,00011,055,000-1,169,0009,628,0002,452,0001,283,000-2,491,000-382,0003,750,0004,971,0001,896,000-2,219,000
Tax2,387,000-3,353,000-4,145,000-2,312,000-2,080,000-94,000-1,780,00076,000-139,000-185,000390,000-4,000667,000915,0000
Profit After Tax-8,849,00016,633,00020,386,0008,024,0008,975,000-1,263,0007,848,0002,528,0001,144,000-2,676,0008,0003,746,0005,638,0002,811,000-2,219,000
Dividends Paid000003,282,000000000000
Retained Profit-8,849,00016,633,00020,386,0008,024,0008,975,000-4,545,0007,848,0002,528,0001,144,000-2,676,0008,0003,746,0005,638,0002,811,000-2,219,000
Employee Costs37,399,00035,280,00030,618,00026,370,00019,408,00021,680,00016,032,00013,921,00012,591,00011,776,00011,846,00012,083,00012,525,00011,931,00011,796,000
Number Of Employees654624560494417388366333299272279296304299278
EBITDA*12,592,00034,575,00035,381,00018,632,00016,400,00010,093,00012,304,0004,818,0003,941,000-192,0003,273,0007,308,0008,910,0005,300,000-534,000

* Earnings Before Interest, Tax, Depreciation and Amortisation

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Tangible Assets84,766,00083,488,00070,286,00058,717,00041,311,00027,531,00021,786,00015,630,00013,977,00012,470,00012,190,00012,491,00013,275,00012,487,00012,212,000
Intangible Assets468,000000000008,000250,000517,0001,046,0001,576,000-232,000
Investments & Other112,705,000107,179,00060,181,00060,145,0003,772,0003,772,000000000000
Debtors (Due After 1 year)61,279,00032,684,00042,468,00029,771,0006,234,0004,743,000375,00001,018,0001,897,0001,968,0001,582,000000
Total Fixed Assets259,218,000223,351,000172,935,000148,633,00051,317,00036,046,00022,161,00015,630,00014,995,00014,375,00014,408,00014,590,00014,321,00014,063,00011,980,000
Stock & work in progress15,683,00018,462,00017,935,00012,919,0008,881,0007,545,0004,773,0005,149,0003,431,0002,753,0002,203,0002,549,0003,050,0002,909,0004,823,000
Trade Debtors67,135,00070,880,00053,772,00035,819,00022,900,00021,505,00016,968,00014,756,00012,066,0009,947,0007,204,0005,428,0006,523,0009,960,0009,170,000
Group Debtors3,146,000759,000968,000823,000398,000237,000100,00032,000496,000300,000153,000107,000242,000227,0001,680,000
Misc Debtors7,600,0008,054,0005,136,0004,976,0003,763,0004,866,0004,566,0004,656,0003,265,0002,260,0004,909,0002,810,0005,511,0002,268,0001,941,000
Cash8,045,0001,990,0002,210,0007,132,0005,820,0007,131,0001,359,0001,468,00052,0007,000141,000166,000614,000188,000199,000
misc current assets000000000000000
total current assets101,609,000100,145,00080,021,00061,669,00041,762,00041,284,00027,766,00026,061,00019,310,00015,267,00014,610,00011,060,00015,940,00015,552,00017,813,000
total assets360,827,000323,496,000252,956,000210,302,00093,079,00077,330,00049,927,00041,691,00034,305,00029,642,00029,018,00025,650,00030,261,00029,615,00029,793,000
Bank overdraft000000005,927,0008,583,00015,788,00010,095,00010,516,00011,663,0007,548,000
Bank loan00000011,156,0009,062,0001,125,0001,375,00000006,113,000
Trade Creditors 7,509,00015,537,00011,569,0005,987,0005,006,0006,087,0005,585,0007,718,0004,573,0003,156,0002,622,0002,146,0004,600,0003,430,0004,796,000
Group/Directors Accounts134,073,000106,657,00076,749,00063,655,00047,315,00044,338,000552,000661,0009,422,0009,014,000951,000865,0002,635,0006,067,0006,920,000
other short term finances950,0001,222,000320,000000000000000
hp & lease commitments092,000190,000291,000338,000367,000278,000217,00088,00037,00031,0000000
other current liabilities17,475,00030,119,00030,760,00030,925,00016,244,00010,995,0007,601,0006,111,0002,396,0002,852,0002,049,0002,423,0005,398,0006,816,0006,444,000
total current liabilities160,007,000153,627,000119,588,000100,858,00068,903,00061,787,00025,172,00023,769,00023,531,00025,017,00021,441,00015,529,00023,149,00027,976,00031,821,000
loans135,337,00092,685,000075,730,000006,527,0008,445,0004,807,000002,375,0003,550,0003,750,0002,750,000
hp & lease commitments000292,000578,000920,000739,000788,000411,000114,000155,0000000
Accruals and Deferred Income0000000322,000417,000516,000496,000828,000390,000355,000499,000
other liabilities0075,822,000000000000000
provisions13,691,00016,543,00013,538,0009,800,0008,000,0008,000,000000000000
total long term liabilities149,028,000109,228,00089,360,00085,822,0008,578,0008,920,0007,266,0009,555,0005,635,000630,000651,0003,203,0003,940,0004,105,0003,249,000
total liabilities309,035,000262,855,000208,948,000186,680,00077,481,00070,707,00032,438,00033,324,00029,166,00025,647,00022,092,00018,732,00027,089,00032,081,00035,070,000
net assets51,792,00060,641,00044,008,00023,622,00015,598,0006,623,00017,489,0008,367,0005,139,0003,995,0006,926,0006,918,0003,172,000-2,466,000-5,277,000
total shareholders funds51,792,00060,641,00044,008,00023,622,00015,598,0006,623,00017,489,0008,367,0005,139,0003,995,0006,926,0006,918,0003,172,000-2,466,000-5,277,000
Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Operating Activities
Operating Profit6,166,00030,184,00031,225,00016,579,00014,129,0008,310,00011,174,0004,141,0002,564,000-1,469,000617,0004,595,0006,643,0003,710,000-1,871,000
Depreciation6,426,0004,391,0004,156,0002,053,0002,271,0001,783,0001,130,000677,0001,369,0001,035,0002,165,0002,183,0001,737,0001,641,0001,444,000
Amortisation000000008,000242,000491,000530,000530,000-51,000-107,000
Tax2,387,000-3,353,000-4,145,000-2,312,000-2,080,000-94,000-1,780,00076,000-139,000-185,000390,000-4,000667,000915,0000
Stock-2,779,000527,0005,016,0004,038,0001,336,0002,772,000-376,0001,718,000678,000550,000-346,000-501,000141,000-1,914,0004,823,000
Debtors26,783,00010,033,00030,955,00038,094,0001,944,0009,342,0002,565,0002,599,0002,441,000170,0004,307,000-2,349,000-179,000-336,00012,791,000
Creditors-8,028,0003,968,0005,582,000981,000-1,081,000502,000-2,133,0003,145,0001,417,000534,000476,000-2,454,0001,170,000-1,366,0004,796,000
Accruals and Deferred Income-12,644,000-641,000-165,00014,681,0005,249,0003,394,0001,168,0003,620,000-555,000823,000-706,000-2,537,000-1,383,000228,0006,943,000
Deferred Taxes & Provisions-2,852,0003,005,0003,738,0001,800,00008,000,000000000000
Cash flow from operations-32,549,00026,994,0004,420,000-8,350,00015,208,0009,781,0007,370,0007,342,0001,545,000260,000-528,0005,163,0009,402,0007,327,000-6,409,000
Investing Activities
capital expenditure-8,172,000-17,593,000-15,725,000-19,459,000-16,051,000-7,528,000-7,358,000-1,688,000-2,474,000-1,315,000-2,088,000-1,400,000-2,525,000-3,673,000-13,317,000
Change in Investments5,526,00046,998,00036,00056,373,00003,772,000000000000
cash flow from investments-13,698,000-64,591,000-15,761,000-75,832,000-16,051,000-11,300,000-7,358,000-1,688,000-2,474,000-1,315,000-2,088,000-1,400,000-2,525,000-3,673,000-13,317,000
Financing Activities
Bank loans00000-11,156,0002,094,0007,937,000-250,0001,375,000000-6,113,0006,113,000
Group/Directors Accounts27,416,00029,908,00013,094,00016,340,0002,977,00043,786,000-109,000-8,761,000408,0008,063,00086,000-1,770,000-3,432,000-853,0006,920,000
Other Short Term Loans -272,000902,000320,000000000000000
Long term loans42,652,00092,685,000-75,730,00075,730,0000-6,527,000-1,918,0003,638,0004,807,0000-2,375,000-1,175,000-200,0001,000,0002,750,000
Hire Purchase and Lease Commitments-92,000-98,000-393,000-333,000-371,000270,00012,000506,000348,000-35,000186,0000000
other long term liabilities0-75,822,00075,822,000000000000000
share issue00000-6,321,0001,274,000700,0000-255,0000000-3,058,000
interest-17,402,000-10,198,000-6,694,000-6,243,000-3,074,000-1,896,000-1,546,000-1,689,000-1,281,000-1,022,000-999,000-845,000-1,672,000-1,814,000-1,697,000
cash flow from financing52,302,00037,377,0006,419,00085,494,000-468,00018,156,000-193,0002,331,0004,032,0008,126,000-3,102,000-3,790,000-5,304,000-7,780,00011,028,000
cash and cash equivalents
cash6,055,000-220,000-4,922,0001,312,000-1,311,0005,772,000-109,0001,416,00045,000-134,000-25,000-448,000426,000-11,000199,000
overdraft0000000-5,927,000-2,656,000-7,205,0005,693,000-421,000-1,147,0004,115,0007,548,000
change in cash6,055,000-220,000-4,922,0001,312,000-1,311,0005,772,000-109,0007,343,0002,701,0007,071,000-5,718,000-27,0001,573,000-4,126,000-7,349,000

sterling pharma solutions limited Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for sterling pharma solutions limited. Get real-time insights into sterling pharma solutions limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Sterling Pharma Solutions Limited Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for sterling pharma solutions limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in NE23 area or any other competitors across 12 key performance metrics.

sterling pharma solutions limited Ownership

STERLING PHARMA SOLUTIONS LIMITED group structure

Sterling Pharma Solutions Limited has 3 subsidiary companies.

STERLING PHARMA SOLUTIONS LIMITED Shareholders

saffron bidco limited 100%

sterling pharma solutions limited directors

Sterling Pharma Solutions Limited currently has 2 directors. The longest serving directors include Mr Kevin Cook (Oct 2014) and Mr Matthew Anderson (Nov 2024).

officercountryagestartendrole
Mr Kevin Cook60 years Oct 2014- Director
Mr Matthew AndersonUnited Kingdom53 years Nov 2024- Director

P&L

March 2024

turnover

115.5m

-11%

operating profit

6.2m

-80%

gross margin

26.4%

-25.62%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

51.8m

-0.15%

total assets

360.8m

+0.12%

cash

8m

+3.04%

net assets

Total assets minus all liabilities

sterling pharma solutions limited company details

company number

05712796

Type

Private limited with Share Capital

industry

21100 - Manufacture of basic pharmaceutical products

incorporation date

February 2006

age

19

incorporated

UK

ultimate parent company

accounts

Full Accounts

last accounts submitted

March 2024

previous names

shasun pharma solutions limited (September 2016)

accountant

-

auditor

PRICEWATERHOUSECOOPERS LLP

address

dudley, cramlington, northumberland, NE23 7QG

Bank

-

Legal Advisor

-

sterling pharma solutions limited Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 22 charges/mortgages relating to sterling pharma solutions limited. Currently there are 3 open charges and 19 have been satisfied in the past.

sterling pharma solutions limited Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for STERLING PHARMA SOLUTIONS LIMITED. This can take several minutes, an email will notify you when this has completed.

sterling pharma solutions limited Companies House Filings - See Documents

datedescriptionview/download